Healthtech Fundraising Story: How to Build One Investors Fund

A healthtech fundraising story is a short, evidence-backed argument that a specific buyer has a costly clinical or operational problem, that your product solves it in a way that can be measured, and that this round gets you to the next proof point. Investors do not fund technology. They fund a believable path from a clinical problem to someone's budget.

I have sat on both sides of this conversation: at the bedside, and in rooms where healthcare software gets bought and funded. The founders who raise well rarely have the most advanced product. They have the clearest story.

The StartupMD

Build a Stronger Healthtech Fundraising Story

The StartupMD advises healthcare SaaS startups on growth challenges, including fundraising, with expertise in medicine and business.

Explore The StartupMD

TL;DR

Open with a quantified problem for a named buyer, not with your algorithm or platform.
Show who uses, who buys and who pays, and put a number on the buyer's return.
Match your proof to your stage: early signals at pre-seed, retention and unit economics by Series A.
Treat regulation and reimbursement as a plan with evidence, not a slide.
Tie the round to milestones that change the company's value, then ask for a specific amount.

What a healthtech fundraising story actually has to do
Start with the buyer's problem, not your technology
Connect the clinical problem to measurable value
Match your proof to your funding stage
Explain who pays: business model, reimbursement and regulation
Use traction honestly
Write the ask like a plan
Common mistakes that weaken the story
A founder's checklist before you send the deck
Perspective
Work with a physician leader on your story
FAQ
Sources

What a healthtech fundraising story actually has to do

A story in this market has one job: reduce the investor's uncertainty. Healthcare adds more uncertainty than most software categories. Sales cycles are long, buyers and payers differ, and clinical claims carry legal weight.

A guide built on more than 100 U.S. healthcare startup decks describes six pillars in funded decks: a quantified problem and solution, a sized market, traction or validation, a business model that shows who pays, a team with clinical, regulatory and operational depth, and a clear competitive position. That list is a good checklist for the story, because each pillar answers a question an investor is already asking.

Your narrative should flow in a predictable order:

The problem, in dollars, hours or outcomes, for one buyer.
The status quo, meaning what that buyer does today and why it fails.
Your solution, described by what changes in the workflow.
Proof, matched to your stage.
The business model, including who pays.
The path to market, including regulation and reimbursement.
The ask, tied to milestones.

If you want the broader framing of how the medical side of the story fits together, our guide to the investor medical narrative goes deeper.

Start with the buyer's problem, not your technology

The most common opening mistake is a product tour. Investors who review healthcare pitches hear the same technology claims repeatedly. What they rarely hear is a precise description of a problem that costs a particular stakeholder money.

Advice aimed at founders pitching AI in healthcare says to open with a concrete, quantifiable problem for a specific buyer rather than the algorithm, then show why solving it makes economic sense. I agree, and I would add one clinical filter: describe the problem as the buyer's day experiences it.

Compare two openings.

Technology first: "Our AI platform uses machine learning to optimize care coordination."
Problem first: "Our target health systems lose patients between referral and first visit. We measured the gap at a design-partner site and it is the single largest source of preventable delay in their specialty clinic."

The second only works if the number is real. If you do not have it yet, say what you are measuring and when it will exist. A hypothesis labeled as a hypothesis builds more trust than a statistic nobody can trace.

Name the status quo

Every buyer already has a way of handling the problem: spreadsheets, extra staff, a legacy vendor, or doing nothing. If your story never names it, investors fill in the blank themselves, and usually with "good enough." Name the alternative by type, say what it costs, and explain why it breaks at scale.

Connect the clinical problem to measurable value

This is where clinical founders and technical founders both get stuck. Clinicians tend to lead with outcomes. Engineers lead with features. Investors, and the people who sign purchase orders, want economics.

A university healthcare technology talk from Carnegie Mellon's entrepreneurship center frames the test simply: assess whether the problem costs a stakeholder money or creates revenue, how painful it is, and where it ranks among that stakeholder's priorities, then present a correctly calculated ROI focused on bottom-line impact.

Clinical results are only one input to a purchase. As Medical Economics notes, healthcare organizations also weigh upfront spending, training and workflow change, and they look through the economic decision-maker's eyes. The same piece makes a point that trips up many decks: time saved does not automatically equal money saved, because staffing, capacity and operations determine whether saved minutes turn into dollars.

A translation exercise you can do this week

Take your headline clinical claim and rewrite it for each person in the buying process.

Stakeholder	What they ask	What your story must show
Clinician user	Does this fit my workflow?	Minutes per task, clicks, adoption in pilot
Clinical leader	Does it change decisions or outcomes?	A specific, actionable change in care
CFO or budget owner	What moves on my P&L?	Cost, throughput or revenue effect with a payback period
Payer or purchaser	Will it change cost or quality for my members?	Outcomes and resource use tied to coverage criteria
Compliance and IT	Is it safe and integrable?	Privacy posture, integration path, regulatory status

One message aimed at everyone persuades no one. Build the core story, then adapt the emphasis for the person in the room.

Be specific about the mechanism

"Improves outcomes" is not a mechanism. "Catches deterioration earlier, which shifts a share of admissions to a lower-cost setting" is. Use the verbs investors can model: earlier diagnosis, prevented escalation, shifted site of care, better adherence, added capacity. Then show the chain from your product to that verb to a cost line.

Match your proof to your funding stage

Investors expect different evidence at different points. Showing Series B metrics at pre-seed looks unrealistic. Showing pre-seed vision at Series A looks late.

The pitch-deck guide above says proof shifts by stage: pre-seed decks lean on vision, team and early signals such as pilots, and run roughly ten slides. Seed adds an MVP, early metrics and an indicative regulatory path. Series A highlights product-market fit through ARR, net revenue retention, CAC and LTV. Series B proves the model scales.

Healthtech fundraising evidence across four stages

Rock Health's research on early-stage digital health shows what that progression looks like in practice. Among respondents, Series B companies averaged 81% recurring revenue versus 54% at Series A. Ninety-four percent tracked outcomes, including engagement (82%), clinical (77%) and economic outcomes (60%). The takeaway for your story: outcomes tracking is nearly universal, but economic outcomes lag. A founder who can show the economics has an edge.

What this means in practice

Pre-seed: a sharp problem, a credible team with clinical and operational depth, and a pilot or design-partner conversation.
Seed: early usage data, a defined first customer segment, and a realistic regulatory read.
Series A: repeatable sales, retention, and a payback story a buyer can verify. Our Series A milestones playbook covers what to have in hand.
Series B: proof the model holds across customers, geographies or service lines.

Build evidence in layers

Do not try to prove everything at once. Sequence it: reliable software first, then evidence that clinical decisions change, then evidence that results hold outside a pilot, then evidence that the economics move for whoever pays. Each layer unlocks the next decision. For the clinical side, see our notes on clinical evidence building and study design for startups.

Explain who pays: business model, reimbursement and regulation

In healthcare, the user, the buyer and the payer are often three different people. Your story has to say which is which, what incentives each has, and what it takes to buy, implement and pay for the product.

Regulatory clearance does not answer the payment question. The NIH's reimbursement knowledge guide for medical devices stresses that reimbursement depends on payer coverage policies and that planning should start early, around the intended patient population and the providers and payers involved. Even if your product is software rather than a device, the lesson carries: investors will ask who reimburses or budgets for this, and when.

A practical way to handle it in the deck:

State your revenue model plainly: subscription, per-member, per-use, or a share of savings.
Identify the economic buyer and the typical budget line the money comes from.
Separate what is proven from what is still a hypothesis. Mark each regulatory and reimbursement assumption accordingly.
Describe the go-to-market motion and how it scales: direct sales, channel, or a land-and-expand approach inside a system.

Treat regulation as a plan with owners and dates, not a slide. If you are unsure how your product will be classified or what evidence it will need, that is exactly where early regulatory guidance pays for itself.

Use traction honestly

Traction is the part of the story investors trust most and scrutinize hardest. A healthtech blog on value stories suggests wrapping your narrative around tangible, completed examples, such as projects delivered on schedule, partnerships and clearances, and tying financial forecasts to your roadmap. It also lists study results, user growth, letters of intent and revenue as ways to show fit.

The rule I give founders: claim only the validation you have. A signed letter of intent is not revenue. A pilot with engagement data is not proof of clinical effect. Say exactly what each piece of traction shows and what it does not yet show. Investors who do diligence will find the gap anyway, and they will remember who volunteered it.

What an evidence-led raise looks like

Public funding coverage shows how evidence can anchor a round. When TechCrunch covered a $45 million Series C for Koneksa, the article highlighted the company's focus on validating digital biomarkers. It cited earlier work suggesting at-home spirometry readings could be comparable to clinic readings, and an activity-tracking study linking at-home measures to clinically meaningful insights. The pattern is worth copying: lead with what the data supports, and be clear about what validation is still ahead.

Write the ask like a plan

The closing slide is where many stories go soft. A pitch-deck advice roundup from Business Insider reports that ask slides should include specific, quantifiable goals for what the funding will achieve and how resources will be allocated to reach next-stage milestones.

A strong ask has four parts:

The amount, tied to a runway window.
The milestones, stated as proof points: customers signed, a study read out, a regulatory step, a retention threshold.
The allocation, by function, linked to those milestones.
The next round, meaning what you will be able to show when you return to market.

Raise for value-inflection milestones, not for activity. "Hire eight people" is activity. "Convert three pilots to paid contracts and publish a cohort outcome analysis" is a milestone.

Common mistakes that weaken the story

These show up again and again in the decks founders bring us.

Leading with the company, not the buyer. Start with the buyer's week and the problem in it.
Showing clinical validation before the problem it answers. Proof lands only after the pain is clear.
One message for every audience. The clinical buyer and the economic buyer need different framing.
Never naming the status quo. If you do not define the alternative, the investor assumes it works.
Burying the number. The ROI belongs up front, not on slide 14 after a workflow walkthrough.
Overbroad claims. "Improves outcomes" with no evidence plan is a credibility risk and, depending on the claim, a regulatory one. Use a claims ladder: start with the smallest claim you can substantiate and climb as evidence grows.
Ignoring privacy and integration. Buyers will ask about both, so address them before they do.
No narrow wedge. A focused first use case beats a platform vision with no beachhead.

Storytelling craft matters too, and general principles on storytelling and brand engagement apply here: one clear protagonist, one tension, one resolution. In healthtech, the protagonist is the buyer and the tension is a costly clinical gap.

A founder's checklist before you send the deck

Run your draft through these questions.

Can an investor repeat your problem statement, with its number, after one read?
Have you named the user, buyer and payer separately?
Does each claim have a source, a data point or a plan to get one?
Is your ROI calculated from the buyer's cost lines rather than from generic industry figures?
Does the regulatory and reimbursement section separate facts from assumptions?
Does each use of funds line map to a milestone?
Would a skeptical clinician on the investor's advisory network find anything overstated?

That last question matters. Many firms ask a physician to review healthcare deals. A story that passes clinical scrutiny moves faster.

Perspective

Founders often ask us whether the story or the data matters more. In healthcare, they are the same thing. A story with no evidence is a pitch, and evidence with no story is a spreadsheet.

What we see most often is a gap between what the founder knows clinically and what the investor can verify. A physician leader closes that gap by translating clinical insight into a claim that has a buyer, a mechanism and a number, and by being candid about what is still unproven. That candor builds credibility with sophisticated investors.

This is the reason we built The StartUp MD around hands-on medical leadership grounded in real patient care and startup growth experience. As a fractional Chief Medical Officer, we work with founders on clinical strategy, evidence planning, regulatory guidance, market readiness and investor support, so the narrative in the deck matches what the product and the clinical team can deliver.

If your story feels misaligned, whether the problem is too broad, the evidence is thin in one layer or the economics are not landing, I would welcome a conversation.

Paul Bergeron MD, MBA

Work with a physician leader on your story

If you are preparing to raise, or advising portfolio companies that are, we provide Fractional Chief Medical Officer leadership and advisory services for healthcare SaaS and healthtech companies. That includes clinical strategy, product evaluation, regulatory guidance, clinical operations consulting, market readiness assessment, investor support, and executive and board advising.

The StartupMD

See how an engagement works on our services page. If you are building the board and investor materials alongside the raise, our healthtech board deck guide and clinical operations guide are good next reads.

FAQ

What is a fundraising story for a healthtech startup?

It is the narrative that links a costly clinical or operational problem to your solution, your proof and your funding plan. It explains who uses, buys and pays, and what the round will accomplish. The deck is how you tell it, but the logic should hold even without slides.

How much clinical evidence do I need before raising?

It depends on your stage and your claims. Pre-seed investors mostly look for team strength and early signals like pilots, while later rounds expect outcomes, retention and economic data. Build proof in layers and claim only what you can support. A physician advisor can help decide the smallest claim that unlocks your next decision.

Should I explain reimbursement in an early-stage pitch?

Yes, in plain terms. Say who pays today, what budget the money comes from and which assumptions about coverage or purchasing are still unproven. Investors know early reimbursement answers are incomplete. They want to see that you have a plan and are collecting the right evidence.

What is the biggest mistake in a healthtech pitch?

Leading with technology instead of the buyer's problem. Investors fund solutions to costly problems for identifiable buyers. Open with the problem in numbers, name what buyers do today, then show your approach.

Who should review my story before I send it to investors?

Someone who can read it as both a clinician and an investor. A fractional CMO or physician advisor can test whether the clinical claims are accurate, the evidence matches the claims and the economics make sense to a budget owner.